Clinical Trial Update: Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial evaluating topical rapamycin for inflammation reversal and epigenetic clock resetting; study completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aging

Drugs mentioned

• Topical-RAPA (rapamycin)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Aging, Epigenetics | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2023-07-19